AIM ImmunoTech's Ampligen Shows Promise in Breast Cancer Study
OCALA, Fla. — AIM ImmunoTech Inc. (NYSE American: AIM) recently celebrated a significant milestone in breast cancer research as data from a Phase 1 study at Roswell Park Comprehensive Cancer Center was published in The Journal for ImmunoTherapy of Cancer. This study focuses on early-stage triple-negative breast cancer (TNBC) and evaluates the effectiveness of Ampligen (rintatolimod), AIM’s leading investigational drug, as part of a chemokine-modulating regimen.
Promising Results from Initial Study
Dr. Shipra Gandhi, the principal investigator at Roswell Park, expressed enthusiasm regarding the results, which indicate the potential of this new treatment combination. "We are very excited with these promising results from our study of a new treatment combination for patients with this most aggressive form of breast cancer, triple-negative breast cancer," she noted. While the findings are encouraging, she emphasized the need for further validation in larger studies.
The Role of Ampligen
AIM’s CEO Thomas K. Equels highlighted the transformative potential of Ampligen in modifying the tumor environment. He stated, “The results of this pilot study suggest that the Ampligen-containing chemokine modulation regimen is capable of modifying the tumor microenvironment and releasing cytokines that attract killer T-cells into the early-stage TNBC tumor.” Equels also pointed out similarities with previous research showing Ampligen's effectiveness in treating advanced-stage TNBC and other cancers.
Looking Ahead: Phase 2 Studies
As AIM ImmunoTech prepares to advance this research to Phase 2 trials, there is optimistic anticipation among cancer experts. The initial findings set a promising foundation for ongoing collaboration with Roswell Park, aiming to expand the understanding of Ampligen's capabilities in conjunction with various chemotherapy regimens and immune checkpoint inhibitors.
Understanding Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center has a rich history of pioneering cancer research and treatment. Establishing its reputation in the late 19th century, it has contributed significantly to advancements in chemotherapy and cancer biomarkers. The center is dedicated to ensuring that innovative cancer care is accessible to patients not just in New York State, but globally.
Commitment to Patient-Centered Care
The 4,000 professionals at Roswell Park are committed to transforming the landscape of cancer treatment. This commitment encompasses comprehensive services aimed at prevention, treatment, and research, illustrating their aggressive approach to eliminating cancer and enhancing patient outcomes.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is at the forefront of immunotherapy, focusing on the development of treatments that address various cancers, immune disorders, and viral diseases, including COVID-19. Its flagship product, Ampligen, has garnered attention for its promising application across multiple clinical trials. AIM is dedicated to bringing innovative therapies to the market that can make a difference in the lives of patients worldwide.
Frequently Asked Questions
What is Ampligen?
Ampligen is an investigational drug by AIM ImmunoTech, recognized for its role as a TLR3 agonist with potential applications in treating various cancers and viral diseases.
What type of breast cancer was studied?
The focus of the study was on early-stage triple-negative breast cancer (TNBC), which is known for being particularly aggressive and challenging to treat.
Who conducted the study?
The study was conducted at Roswell Park Comprehensive Cancer Center, under the guidance of Dr. Shipra Gandhi.
When will the next phases of the study occur?
The transition to Phase 2 studies will depend on the outcomes of the current pilot study and progress discussions between AIM ImmunoTech and Roswell Park.
How can I learn more about AIM ImmunoTech?
For more information, you can visit their official website at aimimmuno.com or reach out through their various social media platforms.
